Sodium benzoate/sodium phenylacetate - MAIA Pharmaceuticals
Alternative Names: Sodium phenylacetate/sodium benzoate - MAIA Pharmaceuticals; Sodium phenylacetate/sodium benzoate 20ml; SPSB liquidLatest Information Update: 25 May 2023
At a glance
- Originator MAIA Pharmaceuticals
- Class Benzoates; Esters; Hepatoprotectants; Neuroprotectants; Phenylacetates; Small molecules; Sodium compounds
- Mechanism of Action Ammonia scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperammonaemia
Most Recent Events
- 25 May 2023 Chemical structure information added
- 28 Sep 2022 Launched for Hyperammonaemia (Adjunctive treatment, In adolescents, In children, In infants, In neonates, In adults) in USA (IV)
- 26 Sep 2022 Fosun Pharma USA enters into a marketing agreement with MAIA Pharmaceuticals for the commercial rights of Sodium phenylacetate/sodium benzoate in USA before September 2022